Do analysts prefer FARN or PRTC?

PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 368.03%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Faron Pharmaceuticals Oy 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 PureTech Health 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Does the media favor FARN or PRTC?

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 1 mentions for PureTech Health. Faron Pharmaceuticals Oy's average media sentiment score of 0.30 beat PureTech Health's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Faron Pharmaceuticals Oy 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PureTech Health 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CIR or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Circassia Group's return on equity. Company Net Margins Return on Equity Return on Assets Circassia Group N/A N/A N/A Faron Pharmaceuticals Oy N/A 476.49% -70.00%

Is FARN or TILS more profitable?

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Tiziana Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals Oy N/A 476.49% -70.00% Tiziana Life Sciences N/A N/A N/A

Does the media favor FARN or TILS?

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 1 mentions for Tiziana Life Sciences. Faron Pharmaceuticals Oy's average media sentiment score of 0.30 beat Tiziana Life Sciences' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Faron Pharmaceuticals Oy 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tiziana Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, VSN or FARN?

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Verseon N/A N/A N/A -£14.30 N/A Faron Pharmaceuticals Oy N/A N/A -£60.23M -£11.52 N/A

Is VSN or FARN more profitable?

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Verseon's return on equity. Company Net Margins Return on Equity Return on Assets Verseon N/A N/A N/A Faron Pharmaceuticals Oy N/A 476.49% -70.00%

Faron Pharmaceuticals Oy (FARN) Competitors

GBX 35.30 -1.20 (-3.29%)

As of 11:53 AM Eastern

Compare

FARN vs. PRTC, ARIX, CIR, TILS, and VSN

Should you buy Faron Pharmaceuticals Oy stock or one of its competitors? Faron Pharmaceuticals Oy's main competitors and comparable companies include PureTech Health (PRTC), Arix Bioscience (ARIX), Circassia Group (CIR), Tiziana Life Sciences (TILS), and Verseon (VSN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Faron Pharmaceuticals Oy (LON:FARN) and PureTech Health (LON:PRTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

Faron Pharmaceuticals Oy has higher earnings, but lower revenue than PureTech Health. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£11.52	N/A
PureTech Health	£6.37M	41.81	-£91.86M	-£46.00	N/A

PureTech Health has a net margin of 7.53% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat PureTech Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	476.49%	-70.00%
PureTech Health	7.53%	0.14%	-13.39%

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than PureTech Health. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 1 mentions for PureTech Health. Faron Pharmaceuticals Oy's average media sentiment score of 0.30 beat PureTech Health's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Faron Pharmaceuticals Oy	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Faron Pharmaceuticals Oy has a beta of 1.116, indicating that its share price is 12% more volatile than the broader market. Comparatively, PureTech Health has a beta of 0.771, indicating that its share price is 23% less volatile than the broader market.

PureTech Health has a consensus target price of GBX 508, suggesting a potential upside of 368.03%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts clearly believe PureTech Health is more favorable than Faron Pharmaceuticals Oy.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Faron Pharmaceuticals Oy	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 30.7% of PureTech Health shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 13.4% of PureTech Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

PureTech Health beats Faron Pharmaceuticals Oy on 9 of the 15 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Faron Pharmaceuticals Oy (LON:FARN) and Arix Bioscience (LON:ARIX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Faron Pharmaceuticals Oy had 4 more articles in the media than Arix Bioscience. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 0 mentions for Arix Bioscience. Faron Pharmaceuticals Oy's average media sentiment score of 0.30 beat Arix Bioscience's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Overall Sentiment
Faron Pharmaceuticals Oy	Neutral
Arix Bioscience	Neutral

Arix Bioscience has a net margin of 105.64% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Faron Pharmaceuticals Oy's return on equity of 476.49% beat Arix Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	476.49%	-70.00%
Arix Bioscience	105.64%	6.41%	2.18%

3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Arix Bioscience has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£11.52	N/A
Arix Bioscience	£14.16M	0.00	£14.96M	£0.11	N/A

Faron Pharmaceuticals Oy has a beta of 1.116, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

Summary

Arix Bioscience beats Faron Pharmaceuticals Oy on 8 of the 12 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Circassia Group (LON:CIR) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Circassia Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Circassia Group	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	476.49%	-70.00%

Circassia Group has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Circassia Group	£27.90M	0.00	N/A	£0.01	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£11.52	N/A

3.8% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Faron Pharmaceuticals Oy had 4 more articles in the media than Circassia Group. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 0 mentions for Circassia Group. Faron Pharmaceuticals Oy's average media sentiment score of 0.30 beat Circassia Group's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
Circassia Group	Neutral
Faron Pharmaceuticals Oy	Neutral

Summary

Faron Pharmaceuticals Oy beats Circassia Group on 5 of the 9 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Tiziana Life Sciences?

Faron Pharmaceuticals Oy (LON:FARN) and Tiziana Life Sciences (LON:TILS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

In the previous week, Faron Pharmaceuticals Oy had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 1 mentions for Tiziana Life Sciences. Faron Pharmaceuticals Oy's average media sentiment score of 0.30 beat Tiziana Life Sciences' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Faron Pharmaceuticals Oy	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tiziana Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tiziana Life Sciences has lower revenue, but higher earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£11.52	N/A
Tiziana Life Sciences	-£3.60M	0.00	N/A	-£16.30	N/A

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Tiziana Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Faron Pharmaceuticals Oy	N/A	476.49%	-70.00%
Tiziana Life Sciences	N/A	N/A	N/A

3.8% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Faron Pharmaceuticals Oy beats Tiziana Life Sciences on 8 of the 9 factors compared between the two stocks.

How does Faron Pharmaceuticals Oy compare to Verseon?

Verseon (LON:VSN) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Verseon	N/A	N/A	N/A	-£14.30	N/A
Faron Pharmaceuticals Oy	N/A	N/A	-£60.23M	-£11.52	N/A

3.8% of Faron Pharmaceuticals Oy shares are held by institutional investors. 2.7% of Faron Pharmaceuticals Oy shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Faron Pharmaceuticals Oy's return on equity of 476.49% beat Verseon's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Verseon	N/A	N/A	N/A
Faron Pharmaceuticals Oy	N/A	476.49%	-70.00%

In the previous week, Faron Pharmaceuticals Oy had 4 more articles in the media than Verseon. MarketBeat recorded 4 mentions for Faron Pharmaceuticals Oy and 0 mentions for Verseon. Faron Pharmaceuticals Oy's average media sentiment score of 0.30 beat Verseon's score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company	Overall Sentiment
Verseon	Neutral
Faron Pharmaceuticals Oy	Neutral

Summary

Faron Pharmaceuticals Oy beats Verseon on 7 of the 8 factors compared between the two stocks.

Get Faron Pharmaceuticals Oy News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FARN vs. The Competition

Export

Metric	Faron Pharmaceuticals Oy	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£71.62M	£3.84B	£7.12B	£2.80B
Dividend Yield	N/A	3.64%	2.53%	6.18%
P/E Ratio	-3.06	13.57	274.21	366.19
Price / Sales	N/A	1,293.43	607.93	89,457.53
Price / Cash	20.00	121.76	77.38	27.89
Price / Book	0.02	16.74	10.92	6.85
Net Income	-£60.23M	-£22.67M	£3.50B	£5.89B
7 Day Performance	1.73%	-2.77%	-2.09%	-0.71%
1 Month Performance	-1.12%	-10.47%	-6.33%	16.92%
1 Year Performance	-80.92%	21.88%	9.10%	16.51%

Faron Pharmaceuticals Oy Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FARN Faron Pharmaceuticals Oy	N/A	GBX 35.30 -3.3%	N/A	-79.0%	£71.62M	N/A	N/A	34	News Coverage Gap Up
PRTC PureTech Health	2.7774 of 5 stars	GBX 114.40 -1.4%	GBX 508 +344.1%	-20.1%	£280.49M	£6.37M	N/A	300	News Coverage
ARIX Arix Bioscience	N/A	N/A	N/A	N/A	£183.73M	£14.16M	1,290.91	9
CIR Circassia Group	N/A	N/A	N/A	N/A	£142.66M	£27.90M	3,400.00	111	Gap Down
TILS Tiziana Life Sciences	N/A	N/A	N/A	N/A	£113.85M	-£3.60M	N/A	11	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:FARN) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. PRTC, ARIX, CIR, TILS, and VSN

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Summary

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Summary

How does Faron Pharmaceuticals Oy compare to Tiziana Life Sciences?

Summary

How does Faron Pharmaceuticals Oy compare to Verseon?

Summary

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Faron Pharmaceuticals Oy (FARN) Competitors

FARN vs. PRTC, ARIX, CIR, TILS, and VSN

How does Faron Pharmaceuticals Oy compare to PureTech Health?

Which has stronger valuation and earnings, FARN or PRTC?

Is FARN or PRTC more profitable?

Does the media favor FARN or PRTC?

Which has more risk & volatility, FARN or PRTC?

Do analysts prefer FARN or PRTC?

Do insiders and institutionals hold more shares of FARN or PRTC?

Summary

How does Faron Pharmaceuticals Oy compare to Arix Bioscience?

Does the media prefer FARN or ARIX?

Is FARN or ARIX more profitable?

Do institutionals and insiders believe in FARN or ARIX?

Which has better valuation and earnings, FARN or ARIX?

Which has more risk & volatility, FARN or ARIX?

Summary

How does Faron Pharmaceuticals Oy compare to Circassia Group?

Is CIR or FARN more profitable?

Which has stronger valuation and earnings, CIR or FARN?

Do institutionals & insiders believe in CIR or FARN?

Does the media favor CIR or FARN?

Summary

How does Faron Pharmaceuticals Oy compare to Tiziana Life Sciences?

Does the media favor FARN or TILS?

Which has preferable earnings & valuation, FARN or TILS?

Is FARN or TILS more profitable?

Do insiders & institutionals hold more shares of FARN or TILS?

Summary

How does Faron Pharmaceuticals Oy compare to Verseon?

Which has better earnings and valuation, VSN or FARN?

Do insiders and institutionals have more ownership in VSN or FARN?

Is VSN or FARN more profitable?

Does the media prefer VSN or FARN?

Summary

Media Sentiment Over Time

FARN vs. The Competition

Faron Pharmaceuticals Oy Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools